



RECEIVED

JUL 24 2001

File Copy

TECH CENTER 1600/2900

Sheet 1 of 2

SUBSTITUTE FORM PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

(37 C.F.R. §1.98(b))

Attorney Docket No.

50025/003002

Serial No.

09/839,752

Applicant

Victor J. Dzau et al.

Filing Date

April 19, 2001

Group

1632 1636

IDS Filed

July 16, 2001

Customer No.

21559

## U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
MM	5,683,985	11/04/97	Chu et al.			
MM	5,631,237	05/20/97	Dzau et al.			

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
MM	WO 92/18522	29/10/92	PCT			

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

MM	Barinaga et al., "Gene Therapy for Clogged Arteries Passes Test in Pigs," Science 265:738 (1994).
MM	Bielinska et al., "Regulation of Gene Expression with Double-Stranded Phosphorothioate Oligonucleotides," Science 250:997-999 (1990).
MM	Chien, "Molecular Advances in Cardiovascular Biology," Science 260:916-917 (1993).
MM	Dalton, "Cell Cycle Regulation of the Human cdc2 Gene," The EMBO Journal 11(5):1979-1804 (1992).
MM	Ebbecke et al., European Heart Journal 12:11 (1991).
MM	Hiebert et al., "E1A-dependent Trans-activation of the Human Myc Promoter Is Mediated by the E2f Factor," Proc. Natl. Acad. Sci. U. S. A. 86:3594-3598 (1989).
MM	Hug et al., "Liposomes for the Transformation of Eukaryotic Cells," Biochem. Biophys. Acta 1097:1-17 (1991).
MM	Hutchinson et al., Circulation 86:Suppl. 1 p. I-226 (1992).
MM	Kaneda et al., "Increased Expression of DNA Cointroduced with Nuclear Protein in Adult Rat Liver," Science 243:375-378 (1989).
MM	Libby et al., "A Cascade Model for Restenosis. A Special Case of Atherosclerosis Progression," Circulation 86:III-47 - III-52 (1992).
MM	Mannino et al., "Liposome Mediated Gene Transfer," BioTechniques 6:682-690 (1988).
MM	Milligan et al., "Current Concepts in Antisense Drug Design," J. Med. Chem. 36:1923-1937 (1993).
MM	Morishita et al., "In Vivo Gene Transfer into Intact Blood Vessels: a Novel and Efficient Method," Circulation 86 (Suppl. I):1-227 (1992).

EXAMINER

M. Tharich

DATE CONSIDERED

5/22/02

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.



RECEIVED

JUL 24 2001

TECH CENTER 1600/2900

Sheet 2 of 2

file  
copySUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(MODIFIED) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

(37 C.F.R. §1.98(b))

Attorney Docket No.	50025/003002
Serial No.	09/839,752
Applicant	Victor J. Dzau et al.
Filing Date	April 19, 2001
Group	1632/636
IDS Filed	July 16, 2001
Customer No.	21559

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

- |   |    |   |
|---|----|---|
| ✓ | MM | Mulligan et al., "The Basic Science of Gene Therapy," Science 260:926-932 (1993).   |
| ✓ | MM | Nevins, "E2F: A Link Between the Rb Tumor Suppressor Protein and Viral Oncoproteins," Science 258:424-429 (1992).   |
| ✓ | MM | Ostrowski et al., "Glucocorticoid Regulation of Transcription at an Amplified, Episomal Promoter," Mol. Cell. Biol. 3:2045-2057 (1983).   |
| ✓ | MM | Pagano et al., "Association of cdk2 Kinase with the Transcription Factor E2F During S Phase," Science 255:1144-1147 (1992).   |
| ✓ | MM | Ritzenthaler et al., "Regulation of the $\alpha 1(I)$ Collagen Promoter via a Transforming Growth Factor- $\beta$ Activation Element," J. Biol. Chem. 268:13625-13631 (1993).             |
| ✓ | MM | Ritzenthaler et al., "Transforming-growth-factor- $\beta$ Activation Elements in the Distal Promoter Regions of the Rat $\alpha 1$ Type I Collagen Gene," Biochem. J. 280:157-162 (1991). |
| ✓ | MM | Rubin et al., "Atherosclerosis in Mice: Getting to the Heart of a Polygenic Disorder," Trends in Genetics 10:199-204 (1994).  |
| ✓ | MM | Schwartz et al., "Coronary Restenosis: Prospects for Solution and New Perspectives from a Porcine Model," Mayo Clinic Proceedings 68:54-62 (1993).  |
| ✓ | MM | Stein et al., "Antisense Oligonucleotides as Therapeutic Agents--is the Bullet Really Magical?" Science 261:1004-12 (1993).   |
| ✓ | MM | Sullenger et al., "Overexpression of TAR Sequences Renders Cells Resistant to Human Immunodeficiency Virus Replication," Cell 63:601-608 (1990).  |
| ✓ | MM | Tomita et al., "Direct in Vivo Gene Introduction into Rat Kidney," Biochem. Biophys. Res. Comm. 186:129-134 (1992).   |
| ✓ | MM | Tseng et al., "Antisense Oligonucleotide Technology in the Development of Cancer Therapeutics," Cancer Gene Ther. 1:65-71 (1994).   |
| ✓ | MM | Uhlmann et al., Chemical Reviews 90:543-584 (1990).   |
| ✓ | MM | Weintraub et al., "Retinoblastoma Protein Switches the E2F Site from Positive to Negative Element," Nature 358:259-261 (1992).  |
| ✓ | MM | Wu et al., "Inhibition of <i>In Vitro</i> Transcription by Specific Double-stranded Oligodeoxyribonucleotides," Gene 89:203-209 (1990).   |
| ✓ | MM | Yee et al., "Promoter Interaction of the E1A-inducible Factor E2F and its Potential Role in the Formation of a Multi-component Complex," The EMBO Journal 6:2061-2068 (1987).             |

EXAMINER

M. Marich

DATE CONSIDERED

5/22/02

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.